Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Fast Track
company
About
Fast Track is an information technology company focused on improving and expediting the clinical trials process.
- 1 - 10
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $30.10M
- Industries
- Clinical Trials,Health Care,Information Technology
- Founded date
- Jan 1, 1999
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision: to revolutionize the management of clinical trials.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$34.06M
Fast Track has raised a total of
$34.06M
in funding over 2 rounds. Their latest funding was raised on
May 9, 2003 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 9, 2003 | Series D | $3.96M | 1 | — | — | Detail |
| Apr 26, 2001 | Series C | $30.10M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Fast Track is funded by 1 investors.
ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
